All Resources

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Private Drug Coverage • November 25, 2022

Cost Drivers: Analysis of Private Drug Plans in Canada 2022

Learn more | View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

Learn more | View

Access to Medicine • November 10, 2022

Canadian Drug Access Pathway

…Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days)….

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Jean-Yves Duclos, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Hon. Chrystia Freeland, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Letter to The Honourable Mary Ng, P.C., M.P.

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • November 09, 2022

Ministerial PMPRB Guideline Letter to The Hon. François-Philippe Champagne, P.C., M.P.

Learn more | View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more | View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more | View

Access to Medicine • June 28, 2022

Search for Specific Brand Name Drug Negotiations Status with the pCPA

Use this tool to search for brand name drugs to view their current negotiation status….

Learn more | View

April 28, 2022

Reflections on a Potential Pan-Canadian Drug Formulary: Medicines Industry Response to CADTH Consultation

Learn more | View